Fresenius Medical Care AG & Co. KGaA
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FMS research report →
About the company
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support.
- CEO
- Helen Giza
- IPO
- 1996
- Employees
- 112,035
- HQ
- Bad Homburg, DE
Price Chart
- Market Cap
- $12.00B
- P/E
- 11.34
- P/S
- 0.54
- P/B
- 0.81
- EV/EBITDA
- 5.84
- Div Yield
- 3.83%
- Gross Margin
- 25.96%
- Op Margin
- 10.17%
- Net Margin
- 4.88%
- ROE
- 7.16%
- ROIC
- 5.76%
- Revenue
- $19.63B · 1.51%
- Net Income
- $978.37M · 81.88%
- EPS
- $1.68 · 83.61%
- Op Income
- $1.83B
- FCF YoY
- 0.54%
- 52W High
- $29.07
- 52W Low
- $20.02
- 50D MA
- $22.23
- 200D MA
- $23.73
- Beta
- 0.81
- Avg Volume
- 709.56K
Get TickerSpark's AI analysis on FMS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Renkewitsch Olga | other | 0 |
Our FMS coverage
Recent articles, reports, and earnings notes.
Fresenius Medical Care (FMS): Turnaround Gains, 2026 Transition
Fresenius Medical Care posted a sharp 2025 profitability step-up, but 2026 is a transition year as temporary benefits roll off and rollout costs rise. The stock looks like a measured Buy for investors willing to wait for execution to stick.
Fresenius Medical Care AG & Co. KGaA (FMS) falls 10.2%
Fresenius Medical Care AG & Co. KGaA (FMS) falls after first-quarter results sparked a sharp selloff. Investors focused on weaker U.S. treatment volumes, reported profit declines, and restructuring costs, even as adjusted earnings improved and full-year guidance was reaffirmed.
Want a deeper read on FMS?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.